Spermosens Secures SEK 10.8M in Strategic Investment
Spermosens has announced a SEK 10.8 million directed share issue to fund its growth until 2026.
Sammanfattning
Spermosens has secured SEK 10.8 million through a directed share issue, aiming for cash flow positivity by 2026. Strategic investors include Mount Nebo Capital and UNITY Innovation Alliance.
Spermosens, a pioneering biotechnology company in Sweden, has successfully raised SEK 10.8 million through a directed share issue. This significant investment is set to provide the company with the financial stability needed to accelerate its strategic initiatives and aim for cash flow positivity by the second half of 2026.
The investment round was led by Mount Nebo Capital, a U.S.-based investment firm known for its expertise in high-growth opportunities within the life sciences and healthcare sectors. UNITY Innovation Alliance, a strategic innovation network from Germany, also played a pivotal role in this investment, alongside seven Nordic and German institutional investors and family offices.
The funds will be primarily used to advance the development and commercialization of Spermosens' groundbreaking product, JUNO-Checked, a diagnostic tool designed to enhance fertility treatments. The company plans to utilize the proceeds for ongoing clinical studies, technology optimization, and the establishment of strategic partnerships and licensing agreements.
CEO Tore Duvold expressed his satisfaction with the investment, highlighting the strategic support from UNITY Innovation Alliance as crucial for product development and market entry. The involvement of experienced investors like Mount Nebo Capital further validates Spermosens' innovative approach to fertility diagnostics.
Given the strategic backing and financial stability ensured by this investment, it is recommended to hold Spermosens shares. The company is well-positioned to capitalize on its innovative technology and strategic partnerships, potentially leading to significant long-term value creation.
Källa
Sammanfattning
The Board of Directors of Spermosens has decided to conduct a directed share issue, authorized by an extraordinary general meeting, raising SEK 10.8 million by issuing approximately 1.35 billion new shares at SEK 0.0080 per share. This funding is expected to support the company until the second half of 2026, when it aims to achieve cash flow positivity through license agreements in the global Assisted Reproductive Technology market. The investment consortium is led by Mount Nebo Capital and includes UNITY Innovation Alliance and seven Nordic and German institutional investors and family offices. UIA will provide strategic and operational advice, aiding in product development and market strategy. The funds will be used for clinical studies, technology optimization, validation, and business development. The decision to proceed with a directed share issue, rather than a rights issue, was made after considering various financing options. Spermosens, a biotechnology company focused on fertility diagnostics, aims to enhance fertility treatments with its JUNO-Checked product. Advisors for the transaction include Scalania AG, Bergs Securities AB, and Fram Advokatbyrå.
